Hepatitis C Virus Envelope Protein E2 – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hepatitis C Virus Envelope Protein E2 – Pipeline Review, H2 2016’, provides in depth analysis on Hepatitis C Virus Envelope Protein E2 targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatitis C Virus Envelope Protein E2 , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2

The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aviragen Therapeutics, Inc.

Integrated BioTherapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hepatitis C Virus Envelope Protein E2 Overview 6

Therapeutics Development 7

Hepatitis C Virus Envelope Protein E2 - Products under Development by Stage of Development 7

Hepatitis C Virus Envelope Protein E2 - Products under Development by Therapy Area 8

Hepatitis C Virus Envelope Protein E2 - Products under Development by Indication 9

Hepatitis C Virus Envelope Protein E2 - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Hepatitis C Virus Envelope Protein E2 - Products under Development by Companies 12

Hepatitis C Virus Envelope Protein E2 - Products under Development by Universities/Institutes 14

Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development 22

Aviragen Therapeutics, Inc. 22

Integrated BioTherapeutics, Inc. 23

Hepatitis C Virus Envelope Protein E2 - Drug Profiles 24

BTA-074 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

CIGB-230 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

E-137 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

E-20 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

hepatitis C (strain H77) vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

hepatitis C (virus-like particle) vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

MBL-HCV-1 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Monoclonal Antibody to Target E2 for Hepatitis C - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Hepatitis C Virus Envelope Protein E2 - Dormant Projects 36

Hepatitis C Virus Envelope Protein E2 - Discontinued Products 37

Hepatitis C Virus Envelope Protein E2 - Featured News & Press Releases 38

Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma 38

Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released 38

Jun 10, 2013: IBT and Stanford Awarded STTR 39

Aug 30, 2012: Researchers Develop Monoclonal Antibody That Prevents Hepatitis C In Animal Model 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Aviragen Therapeutics, Inc., H2 2016 22

Pipeline by Integrated BioTherapeutics, Inc., H2 2016 23

Dormant Projects, H2 2016 36

Discontinued Products, H2 2016 37

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports